Medlab Clinical (ASX: MDC) Share Price and News
Price
$6.60
Movement
– ( )
as at 3 Mar - Closed (20 mins delayed)
52 Week Range
– - –
1 Year Return
0.0
Medlab Clinical Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
$6.60
Day Change
– ( )
52 Week Range
– - –
Yesterday's Close
$6.60
Today's Open
–
Days Range
– - –
Volume
0
Avg. Volume (1 month)
0
Turnover
$0
as at 3 Mar - Closed
Medlab Clinical (ASX: MDC)
Latest News
Investing
Here are 2017's best performing ASX pot stocks
Investing
Here's Medlab Clinical Ltd's 'world first' plan to test cannabis on Sydney patients
MDC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
28th Feb 2025 2025-02-28T09:20:07 | Removal from Official List | YesNo | 9:20am | 1 | 547k |
14th Feb 2025 2025-02-14T09:16:05 | Results of Meeting 2024 | YesNo | 9:16am | 2 | 96k |
14th Feb 2025 2025-02-14T09:15:40 | Results of Meeting 2023 | YesNo | 9:15am | 2 | 97k |
3rd Feb 2025 2025-02-03T14:08:11 | Quarterly Activities/Appendix 4C Cash Flow Report | YesNo | 2:08pm | 6 | 353k |
22nd Jan 2025 2025-01-22T16:20:01 | Long Term Suspended Entities | YesNo | 4:20pm | 8 | 206k |
10th Jan 2025 2025-01-10T16:08:40 | Notice of Annual General Meeting/Proxy Form | YesNo | 4:08pm | 13 | 408k |
10th Jan 2025 2025-01-10T16:08:00 | Notice of General Meeting/Proxy Form | YesNo | 4:08pm | 15 | 423k |
13th Dec 2024 2024-12-13T09:54:23 | Response to Appendices 3X and 3Z Query | YesNo | 9:54am | 3 | 812k |
4th Dec 2024 2024-12-04T14:59:09 | Final Director's Interest Notice | YesNo | 2:59pm | 2 | 162k |
4th Dec 2024 2024-12-04T14:58:34 | Initial Director's Interest Notice | YesNo | 2:58pm | 2 | 200k |
About Medlab Clinical
Medlab Clinical Ltd. engages in the development of therapeutic pathways for diagnosed chronic diseases. It operates through the Nutraceutical Sales and Pharmaceutical Research segments. Its products include BifidoBiotic, BioClean, Biotic Jnr., GastroDaily, Lactoferrin Enhanced, Manuka-C, NanoCelle, NeuroActiv, NRGBiotic, and ORSBiotic. The company was founded by Sean Hall on June, 2012 and is headquartered in Botany, Australia.
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Tim Walker | Non-Executive Director | Mar 2024 |
Mr Walker is a corporate finance professional with experience in originating, managing, and leading resource-focused transaction. Specialising in M&A transactions across the Canadian and Australian markets, IPOs, and equity and debt financing solutions. Tim's past directorships with exploration companies have provided him with experience across commodity groups, including lithium exploration, rare earth and niobium hosted carbonatite deposits, whilst also having experience transacting on iron ore and base metal projects.
|
Mr Edmond Tan | Non-Executive Director | Mar 2024 |
Mr Tan is a financial services professional with over 10 years' experience in roles which include Private Wealth Management, Family Office, and Structured Finance. In addition, he was involved in the establishment of a mid-market private equity joint venture fund with a focus on foreign investment into Australia. Currently, Mr Tan is a Director of Regenerate Pty Ltd a rare earth magnet recycling technology based in Houston, Texas. He is also the Australian Representative for Obsidian Global Partners LLC, a structured financier for ASX listed companies.
|
Mr Joshua David Light | Non-Executive Director | Nov 2024 |
Mr Light is a corporate finance with broad expertise in investment banking and corporate advisory, particularly within the mining and resources sector. He has managed and facilitated numerous M&A transactions and capital raisings across primary and secondary markets in Australia and North America. Josh brings a understanding of base and critical metals and has coordinated various resource acquisitions at the junior market level.
|
Mr Kerem Kaya | Chief Financial OfficerCompany Secretary | May 2021 |
-
|
Kerem Kaya | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Mr Sean Michael Hall | 389,041 | 17.04% |
Farjoy Pty Ltd | 205,663 | 9.01% |
HSBC Custody Nominees (Australia) Limited | 88,229 | 3.86% |
UBS Nominees Pty Ltd | 85,316 | 3.74% |
Fit Investments Pty Ltd Hallab Investment A/C | 75,563 | 3.31% |
Realm Group Pty Limited | 54,705 | 2.40% |
Citicorp Nominees Pty Limited | 49,798 | 2.18% |
Mr Drew Anthony Townsend Townsend Family A/C | 37,038 | 1.62% |
Richard Albarran Albarran Family No 2 A/C | 37,038 | 1.62% |
United Trolley Collections P/L | 32,970 | 1.44% |
BNP Paribas Nominees Pty Ltd Ib Au Noms Retailclient | 30,272 | 1.33% |
Mr Michael Jack Hall & Mrs Elizabeth Ann Jones Hall Jones Super Fund A/C | 29,820 | 1.31% |
Netwealth Investments Limited Wrap Services A/C | 20,186 | 0.88% |
Villamagna Inc | 20,000 | 0.88% |
BNP Paribas Noms Pty Ltd | 17,164 | 0.75% |
Daniel P Moses (Nominees) Pty Limited Daniel Moses Family A/C | 16,667 | 0.73% |
Acron Holdings Pty Limited Acron Super Fund A/C | 16,181 | 0.71% |
Kenney Family Investments Pty Ltd Kenney Family Account | 15,295 | 0.67% |
Assumo (Nominees) Pty Ltd Assumo S/Fund A/C | 13,334 | 0.58% |
D J Fairfull Pty Ltd Fairfull Super Fund A/C | 12,651 | 0.55% |